Editas Medicine Inc (NAS:EDIT)
$ 1.199 -0.011 (-0.91%) Market Cap: 99.88 Mil Enterprise Value: -126.72 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 46/100

Editas Medicine Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 12:30AM GMT
Release Date Price: $8.54 (+3.02%)
Gilmore Oâ;Neill
Editas Medicine, Inc. - President & CEO

Okay. Good afternoon, everyone. I am being told to progress, to maintain the clock. And I also understand that I am the last speaker between you and the bar. So even more important that I get this right and follow instructions. Brian, forgive me. I started without you. Sorry.

Lut Ming Cheng
JPMorgan Chase & Co, Research Division - Research Analyst

Not a problem.

Gilmore Oâ;Neill
Editas Medicine, Inc. - President & CEO

I was under instructions, Brian. Okay. So today, Editas is changing. Editas is changing so that we can be the leader in in vivo programmable gene editing leveraging cutting-edge technology. We aim to deliver therapies that revolutionize the treatment of previously untreatable diseases, improve patients' treatment journeys by simplifying the usability of gene editing and minimize the burden on health care systems, all while developing novel, differentiated medicines.

Today, I am pleased to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot